Cargando…

Apatinib Combined With Radiotherapy Enhances Antitumor Effects in an In Vivo Nasopharyngeal Carcinoma Model

Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are highly expressed in nasopharyngeal carcinoma; therefore, blocking the binding of VEGF and VEGFR may be a potential way to treat nasopharyngeal carcinoma. Apatinib inhibits tumor angiogenesis. Previous studies have suggested that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Shanshan, Wu, Fei, Zhang, Yanling, Qin, Rongsheng, Zhu, Nengping, Li, Yuan, Wang, Mingting, Zeng, Qin, Xie, Danna, Li, Yinghua, Fan, Juan, Han, Yunwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235534/ https://www.ncbi.nlm.nih.gov/pubmed/32420748 http://dx.doi.org/10.1177/1073274820922553

Ejemplares similares

Efficacy of granulocyte-macrophage colony-stimulating factor combined with metronomic paclitaxel in the treatment of Lewis lung carcinoma transplanted in mice
por: Zhu, Nengping, et al.
Publicado: (2017)

Antitumor effects of Endostar(rh-endostatin) combined with gemcitabine in different administration sequences to treat Lewis lung carcinoma
por: Li, Yuan, et al.
Publicado: (2019)

Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma
por: Peng, Qiu-Xia, et al.
Publicado: (2017)

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
por: Zhou, Ling, et al.
Publicado: (2023)

Clinical Effect of Apatinib Mesylate Tablets Combined with Paclitaxel Concurrent Radiotherapy and Chemotherapy in the First-Line Treatment of Locally Advanced Nasopharyngeal Carcinoma
por: Zhan, Dechao, et al.
Publicado: (2022)

Update on Radiotherapy Changes of Nasopharyngeal Carcinoma Tumor Microenvironment
por: Zhu, Dao Qi, et al.
Publicado: (2023)

Low‐ dose Apatinib promotes vascular normalization and hypoxia reduction and sensitizes radiotherapy in lung cancer
por: Jiang, Shanshan, et al.
Publicado: (2022)

Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma
por: Wang, Hongzhi, et al.
Publicado: (2022)

Significant efficacy and well safety of apatinib combined with radiotherapy in NSCLC: Case report
por: Zhao, Chunbo, et al.
Publicado: (2017)

Effect of X-ray radiation on the pharmacokinetics of apatinib in vivo in rats
por: Dong, Shi-Qi, et al.
Publicado: (2022)

Prognostic Value of the Site of Distant Metastasis and Surgical Interventions in Metastatic Gastric Cancer: A Population-Based Study
por: Li, Yinghua, et al.
Publicado: (2020)

Efficacy and safety of apatinib combined with radiotherapy in the treatment of advanced pancreatic cancer: a meta-analysis
por: Ma, Yongli, et al.
Publicado: (2023)

Apatinib suppresses cell growth and metastasis and promotes antitumor activity of temozolomide in glioma
por: Wang, Chao, et al.
Publicado: (2018)

Osthole sensitizes with radiotherapy to suppress tumorigenesis of human nasopharyngeal carcinoma in vitro and in vivo
por: Peng, Lin, et al.
Publicado: (2018)

Apatinib alone or combined with radiotherapy in metastatic prostate cancer: Results from a pilot, multicenter study
por: Zhao, Feng, et al.
Publicado: (2017)

Radiotherapy with apatinib for recurrence of malignant phyllodes tumor of the breast: A case report
por: Wu, Hong, et al.
Publicado: (2020)

Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma: A case report
por: Jin, Jun, et al.
Publicado: (2019)

Clinical efficacy and survival analysis of apatinib combined with docetaxel in advanced esophageal cancer
por: Li, Jing, et al.
Publicado: (2019)

Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial
por: Yuan, Li, et al.
Publicado: (2023)

Apatinib is effective for treatment of advanced hepatocellular carcinoma
por: Kong, Yinlong, et al.
Publicado: (2017)

Camrelizumab and Apatinib Combined with Radiotherapy Is Effective in Advanced Oligometastatic Non-Small-Cell Lung Cancer
por: Ye, Wei, et al.
Publicado: (2022)

Effects of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A real-world study
por: Zeng, Fujuan, et al.
Publicado: (2021)

Serum proteomics identify potential biomarkers for nasopharyngeal carcinoma sensitivity to radiotherapy
por: Zhang, Guangying, et al.
Publicado: (2019)

Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma
por: Wang, Yonggang, et al.
Publicado: (2022)

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

Raltitrexed Enhances the Antitumor Effect of Apatinib in Human Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways
por: Zhen, Hongchao, et al.
Publicado: (2020)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
por: Gong, Taojun, et al.
Publicado: (2022)

Apatinib enhances the antitumor effects of radiation in HeLa cell line mouse model of invasive cervical cancer
por: Wang, Yun, et al.
Publicado: (2022)

The effect of apatinib combined with chemotherapy or targeted therapy on non‐small cell lung cancer in vitro and vivo
por: Liu, Mingtao, et al.
Publicado: (2019)

Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma
por: Yang, Chaoxu, et al.
Publicado: (2018)

Apatinib combined with S-1 as second-line therapy in advanced gastric cancer
por: Qiu, Zhi-Yuan, et al.
Publicado: (2021)

Retracted: Camrelizumab and Apatinib Combined with Radiotherapy Is Effective in Advanced Oligometastatic Non-Small-Cell Lung Cancer
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
por: Ding, Xi, et al.
Publicado: (2023)

The efficacy and safety of apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis
por: Lin, Huixiong, et al.
Publicado: (2022)

Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model
por: Jin, Yinghua, et al.
Publicado: (2018)

Effects of intensity-modulated radiotherapy and chemoradiotherapy on attention in patients with nasopharyngeal cancer
por: Wei, Qing, et al.
Publicado: (2017)

Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
por: Yuan, Shumin, et al.
Publicado: (2022)

Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study
por: Liu, Yanfei, et al.
Publicado: (2023)

Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study
por: Zhu, Anjie, et al.
Publicado: (2019)

Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients
por: Pan, Dengdeng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e30s5m46gng1p2lua4dg9pklta